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Inflammatory mediators released from activated mast cells and basophils during hypersensitivity reactions have direct 
pathological effects on the myocardium and coronary vasculature. It was traditionally thought that cardiovascular signs and 
symptoms in anaphylaxis are largely due to peripheral vasodilation and increased vascular permeability. However, there is 
extensive evidence of primary cardiac involvement during hypersensitivity reactions, most notably coronary vasoconstriction 
as well as atherosclerotic plaque erosion and rupture, leading to angina pectoris and acute coronary syndromes. Furthermore, 
mast cells are well established as effector cells in atherosclerosis, through their effects on atherosclerotic plaque progression and 
destabilisation. It was noted over 30 years ago that cardiac patients have a markedly higher concentration of biologic amines 
(especially histamine) in their coronary vasculature, and, additionally, are hyper-reactive to the effects thereof. This is borne out by 
the disproportionate mortality rate of those with cardiac disease that suffer a hypersensitivity reaction. Kounis syndrome refers 
to angina pectoris or an acute coronary syndrome secondary to a hypersensitivity reaction, with the subtypes dependent on the 
underlying state of the coronaries and presence of a drug-eluting stent or not. This review will focus mainly on the aetiology, 
pathophysiology, diagnoses and treatment of this important syndrome.
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Introduction
There is extensive evidence of cardiac involvement in animal (in 
vivo and in vitro) anaphylaxis1–3 as well as human anaphylaxis.4–7 
During anaphylaxis, the heart is both a source and a target of 
released chemical mediators, which have direct effects on the 
coronary vasculature and myocardium.
Kounis syndrome is the concurrent occurrence of acute coronary 
syndromes with hypersensitivity reactions (including 
anaphylaxis).8 Two principal variants of the syndrome are 
described: type 1 is allergy-related angina due to coronary spasm 
with type II being allergy-related myocardial infarction due to 
plaque rupture and thrombus formation. Drug-eluting stent 
thrombosis (late stent thrombosis) secondary to hypersensitivity 
reactions has recently been proposed as a third type.9
Historical background (see Figure 1)
Paul Ehrlich published his seminal description of mast cells in 
1878.10 Anaphylaxis was characterised by Richet and Portier in 
1901, which won Richet the Nobel Prize in 1913.11 In 1913 Auer 
reported ECG changes during animal anaphylaxis.12
The first case of myocardial infarction during an allergic reaction 
in humans was reported in 1950.13 In 1991, Kounis and Zavras 
described a ‘syndrome of allergic angina’ as the simultaneous 
occurrence of chest pain and allergic reactions, accompanied by 
clinical and laboratory findings of angina pectoris, caused by 
inflammatory mediators released during the allergic process.8 
Kovanen in 1995 found much greater coronary mast cell 
degranulation at the sites of erosion or plaque rupture than in 
adjacent areas;14 later Braunwald noted that mediators such as 
histamine or leukotrienes released during allergic reactions 
could induce vasospastic angina by acting on coronary smooth 
muscle.15
In 2002, two variants of the original ‘allergic angina syndrome’ 
were described,16 with drug-eluting stent (DES) thrombosis later 
proposed as a third type.9,17 It was first reported in children in 
2009, including in a two-year-old.18–20
Epidemiology
The lifetime prevalence of anaphylaxis is at least 1.6%, probably 
higher.22 It is increasing in developing countries,23–25 and leading 
to an increased number of UK critical care admissions.26
Perioperative anaphylaxis occurs in 1:3 500–1:20 000 cases, with 
a mortality of 9%.27 It accounts for 9–19% of anaesthetic-
associated complications and 5–7% of deaths during 
anaesthesia.27,28 The most common agents implicated in 
perioperative anaphylaxis are neuromuscular blocking agents 
(58%), latex (19.6%) and antibiotics (12.8%).29
It is difficult to estimate the incidence of Kounis syndrome. It is 
probably under-reported, with anaesthesiologists and 
intensivists generally unaware of the condition. It is not unlikely 
to occur though. Two out of 21 healthy adults developed 
symptoms and ECG changes suggestive of myocardial ischaemia 
during a diagnostic sting challenge.30 In a French survey of 
anaphylaxis under anaesthesia, 73.6% of cases had cardiovascular 
involvement.31 A Swiss study showed an incidence of severe life-
threatening anaphylaxis with circulatory signs of 7.9–9.6 per 100 
000 people per year.6 Many cases go unreported, although 
awareness and reporting is increasing.
Aetiology
Sixty years ago, Pfister reported a case of antero-septal 
myocardial infarction and urticaria four days after treatment with 
penicillin.13 Hundreds of cases of Kounis syndrome have been 
described since, including several case series.32–35
22(3)
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Kounis syndrome has been described secondary to a large 
number of drugs, of various classes (e.g. antibiotics, muscle 
relaxants, anti-neoplastics, contrast media, NSAIDS, 
thrombolytics etc.).21,36,37
Several environmental exposures are linked to the syndrome 
(with Hymenoptera stings accounting for the majority of serious 
reactions); in addition, there are a number of diseases and 
conditions related to Kounis syndrome (e.g. mastocytosis, 
bronchial asthma etc.).36
One can argue that any drug or condition able to provoke an 
allergic reaction can lead to Kounis syndrome. It is well known 
that atopic individuals are at higher risk of acute coronary 
syndromes.38–40
Pathophysiology
Anaphylaxis is a serious, potentially fatal, multi-organ syndrome 
caused by a triggered release of mast cell derived mediators into 
the systemic circulation.41,42 The trigger is either (1) immunologic 
(IgE or IgG dependent) or (2) non-immunologic (direct 
stimulation of mast cells by certain drugs, cold air, exercise, 
etc.).43–46
The immunologic pathway involves an allergen-induced 
crosslinking of IgE antibodies (formed during a clinically silent 
initial exposure) coupled to mast cells and basophils, which 
induces a transduction cascade activating mast cells. Note that a 
very small amount of allergen is needed to trigger the cascade.47
Activated mast cells degranulate and release an array of vasoactive 
and pro-inflammatory mediators, namely (1) preformed granule 
associated mediators, (2) newly generated lipid-derived mediators 
plus (3) cytokines and chemokines (Table 1).48–51
Mast cells are widely distributed in tissues, particularly those 
with external environment contact (i.e. skin, gastrointestinal 
system, lung) but also in other organs such as the heart.49 In the 
heart they are located mainly between myocardial fibres (in close 
proximity to myocytes), around both large coronary vessels and 
small intramural coronary arteries, and in the arterial intima and 
adventitia.49,51,52
Uniquely, heart mast cells can be directly activated by non-
allergenic stimuli (e.g. anaphylatoxins C3a and C5a and substance 
P),49,53 as well as by drugs such as muscle relaxants, protamine 
and radio-contrast media.54 Cardiac mast cells are some of the 
most important effector cells of anaphylaxis.50,55
Effects of mast cell mediators on coronary 
circulation:
Histamine has important context-specific effects on cardiac 
tissues. It dilates coronary arteries (via H1-receptors on vascular 
smooth muscle cells) and causes arrhythmias and atrio-
ventricular conduction blocks in healthy volunteers.56 It further 
leads to a baroreceptor-mediated tachycardia by decreasing 
mean aortic pressure.57
However, in patients with coronary artery disease and vasospastic 
angina, intravenous histamine causes a decrease in coronary 
blood flow, and in some cases severe coronary spasm.56,58
Histamine also induces tissue factor expression in endothelial 
cells and vascular smooth muscle cells, thus mediating thrombus 
formation in acute coronary syndromes.59
Heart mast cells release large quantities of chymase (compared 
with lung and skin), as well as significant quantities of renin,2,60 
activating the cardiac renin-angiotensin-aldosterone system. 
Figure 1: Timeline of Kounis syndrome.21
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Chymase has potent angiotensin-converting enzyme (ACE) 
activity, even in the presence of ACE inhibitors.60 Angiotensin is a 
coronary vasoconstrictor, causes arrhythmias and leads to 
fibrosis and apoptosis.
Platelet activating factor (PAF) causes a significant decrease in 
coronary blood flow and marked negative inotropy; it also has a 
direct arrhythmogenic effect.61 It may also contribute to 
atherosclerotic plaque instability and rupture by inducing local 
platelet aggregation and the release of lytic enzymes by 
macrophages.14 Systemic PAF causes peripheral vasodilatation.62 
One of the major causes of disseminated intravascular 
coagulation in fatal anaphylaxis is PAF-induced platelet 
activation.63 Of note, PAF has shown significant correlation with 
the severity of anaphylaxis, better than either histamine or 
tryptase.64,65
Intravenous or intra-coronary infusion of cysteinyl leukotrienes, 
such as leukotriene D4, leads to a rapid and sustained rise in 
coronary vascular resistance and subsequent decrease in 
coronary blood flow.66,67
Thromboxane causes vasoconstriction and is an important 
mediator of platelet aggregation.68 In experimental animal 
studies, prostaglandin D2 causes coronary vasoconstriction and 
arrhythmias.69
Mast cells in cardiovascular disease
There is increasing evidence of the central role of mast cells and 
their mediators in cardiovascular disease, through their effects 
on atherosclerotic plaque progression and destabilisation.52,70,71
Histamine and tryptase may contribute to fatty streak formation 
and the generation of unstable plaques susceptible to rupture.52 
Activation of matrix metalloproteinases by mast cell derived 
proteases is an important mechanism in atherosclerotic plaque 
destabilisation.72
Higher levels of histamine are found in coronary arteries of 
patients who died from ischaemic heart disease.73 They also have 
more degranulated mast cells at the site of atheromatous 
rupture, compared with adjacent normal intima.14,52 Patients with 
peripheral vascular disease were found to have higher plasma 
levels of histamine compared with controls.74 Mast cell derived 
mediators like histamine, serotonin, leukotrienes and 
prostaglandin D2 contribute to vascular responsiveness; 
increased numbers of mast cells are associated with coronary 
vasospasm.75
Some authors have suggested using tryptase as a biomarker for 
atherosclerosis76 and acute coronary syndromes.77–79 Pre-existing 
cardiovascular disease, mastocytosis and elevated baseline 
serum tryptase are all risk factors for fatal anaphylactic 
reactions.80,81
Hypersensitivity-induced coronary stent 
thrombosis (Kounis type III)
All the components of drug-eluting stents, namely (1) the metal 
strut (composed of nickel, molybdenum and chromium),82 (2) the 
polymer83 and (3) the impregnated paclitaxel/sirolimus,84 can 
elicit hypersensitivity reactions with a release of pro-thrombotic 
mediators like PAF, cytokines and chemokines. Several hundred 
cases of hypersensitivity reactions related to drug-eluting stents 
(DES) have been reported, some of which were fatal.85
Based on human autopsy series, DES late/very late stent thrombosis 
is caused by impaired arterial healing (with characteristic 
incomplete re-endothelialisation, persistent fibrin deposition and 
macrophage infiltration) when compared with bare metal stents.86 
Autopsies confirmed inflammatory cell infiltrates (plasma cells, 
macrophages, eosinophils and lymphocytes) that permeate all 
three vascular wall layers, a histopathological picture very similar 
to Kounis type I and type II.86
Clinical variants
Systemic allergic signs and/or symptoms accompanied by 
clinical, electrocardiographic or laboratory findings of myocardial 
ischaemia constitutes Kounis syndrome.8 Three variants have 
been described (Table 2).9,16,85
Table 1: Mediators released by activated human mast cells (clinically important ones italicised)








•  Heparin proteoglycan
•  Chondroitin sulfate proteoglycan
•  Cathepsin G
Newly generated lipid-derived mediators
•  Platelet activating factor
•  Leucotriene (LT) B4, LTC4, LTD4, LTE4
•  Prostaglandin (PG) D2, PGE2
•  Thromboxanes
Cytokines and chemokines
•  Inflammatory cytokines (interleukin (IL)-4, IL-5, IL-6, IL-13, tumour necrosis factor-α)
•  Chemokines (monocyte chemotactic protein-1, IL-8, RANTES*)
•  Hematopoietic factors (IL-3, granulocyte-macrophage colony-stimulating factor)
•  Growth factors (vascular endothelial growth factor, platelet derived growth factor etc.)
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Transthoracic or trans-oesophageal echocardiography can 
reveal regional wall motion abnormalities suggestive of 
acute coronary syndromes, and can help distinguish 
between other causes of chest pain and/or hypotension 
(such as aortic dissection, pericarditis, pericardial effusion 
and pulmonary embolism).
Coronary angiography will distinguish between types I and II 
Kounis syndrome, as well as being useful to guide therapy 
(e.g. intracoronary calcium channel blockers for vasospasm).
•  Hypersensitivity reaction: Tryptase, histamine levels, specific IgE 
antibody and eosinophil levels will help to identify an allergic 
reaction.
Mast cell tryptase is elevated in most patients with 
systemic anaphylaxis (though not all). Tryptase peaks at 
1–1.5 hours after anaphylaxis onset and remains elevated 
for over 5 hours. The best time to measure is from 1–2 
hours, but no longer than 6 hours after onset. Histamine 
has a half-life of less than 30 minutes89 and is thus not 
commonly measured.
Although PAF correlates better with the severity of 
anaphylaxis than histamine or tryptase,64,65 the extremely 
short half-life precludes its clinical use.48
Anaphylatoxins like C5a can cause mast cell degranulation,90 
thus complement levels may be useful.
Allergologic testing
Allergy testing, such as patch testing, skin prick, intradermal 
testing and serum-specific IgE testing for IgE antibodies should 
be done 4–6 weeks after the reaction (to avoid false negative test 
results because of mast cell depletion). However, mast cells can 
degranulate from direct stimulation (e.g. morphine, codeine), 
leading to the absence of IgE antibodies.91
Diagnosis
There are two aspects to the diagnosis: the hypersensitivity 
reaction plus the myocardial ischaemia. Dewachter suggested a 
triad of evidence to diagnose perioperative anaphylaxis (clinical, 
biologic and allergologic evidence).47 It is important to actively 
look for and anticipate cardiac involvement if anaphylaxis is 
suspected or diagnosed.
Clinical/ECG features
The modified Ring and Messmer clinical severity scale should be 
used to classify signs and symptoms of immediate hypersensitivity 
reactions (Table 3).11,47,87
The diagnosis of anaphylaxis during anaesthesia can be 
challenging, because important features like hypotension or 
bronchospasm have many other, more common causes.88 Note 
that cutaneous signs can be absent in rapidly progressing 
anaphylaxis, further clouding the diagnosis.
ECG changes are integral to the diagnosis of Kounis syndrome, in 
combination with the clinical picture and biochemical markers. 
The syndrome usually presents with changes in the anterior or 
inferior leads, the right coronary artery being commonly 
involved.21
It may also show non-specific ST-segment/T-wave abnormalities, 
atrial fibrillation, nodal rhythms, ventricular ectopics, bigeminy, 
QRS-complex broadening and QT-segment prolongation; rarely 
do patients have a normal ECG.
Special investigations
•  Cardiac: Cardiac enzymes (troponins) should be sent as soon as 
cardiac involvement is suspected. Other blood tests such as 
d-dimer, full blood count, brain natriuretic peptide and serum 
cholesterol levels can be sent after the acute event.
Table 2: Clinical variants of Kounis syndrome
Clinical variant Pathogenesis
Type I: vasospastic allergic angina
Patients with normal or nearly normal coronary arteries without risk factors for 
coronary atherosclerosis in which acute release of inflammatory mediators causes 
coronary spasm; (1) either without a rise in cardiac enzymes or (2) coronary spasm 
leading to an acute myocardial infarction (raise in cardiac enzymes). This may be 
due to endothelial dysfunction or micro-vascular angina
Type II: coronary thrombosis leading to allergic myocardial infarction
Patients with underlying coronary atherosclerosis in which inflammatory mediators 
causes either coronary spasm (with normal cardiac enzymes) or coronary spasm 
and plaque erosion or rupture leading to an acute myocardial infarction
Type III: coronary artery drug-eluting stent thrombosis
Hypersensitivity reaction to one of the components of the stent causing throm-
bosis. Giemsa and haemotoxalin-eosin staining shows mast cells and eosinophils 
respectively in the aspirated stent thrombus
Table 3: Clinical severity scale of immediate hypersensitivity reactions47
Grade Clinical signs
I Muco-cutaneous signs: erythema, urticaria ± angioedema
II Moderate multi-visceral signs: muco-cutaneous signs ± hypotension ± tachycardia ± dyspnoea ± gastrointestinal disturbances
III
Life-threatening mono- or multi-visceral signs: cardiovascular collapse, tachycardia/
bradycardia ± arrhythmias ± bronchospasm ± muco-cutaneous signs ± gastroin-
testinal disturbance
IV Cardiac arrest
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Anaphylaxis guidelines suggest using 100% O2, but routine 
oxygen administration in myocardial infarction may be 
associated with increased mortality.116 Oxygen should thus be 
titrated to normoxia.
Though nitroglycerin may be used for ischaemic pain, it can 
worsen the hypotension of anaphylaxis and should be used 
cautiously.
Opioids such as morphine, codeine and pethidine can induce 
mast cell degranulation and aggravate allergic reactions. 
Fentanyl and its derivatives (with minimal mast cell activation) 
may be better-suited narcotic analgesics.
β blockers offset the beneficial effects of adrenaline in anaphylaxis 
and should be used with extreme caution, if at all. Glucagon can 
be used for patients with anaphylaxis and hypotension who are 
on β blockers.107
Long-acting calcium channel blockers (CCB) and nitrates are 
generally recommended for patients with hypersensitivity-
induced coronary vasospasm.102 Based on the pathophysiology 
of Kounis syndrome, CCB may be considered as the initial anti-
ischaemic drugs of choice.
Uncoated aspirin should be given to all patients promptly after 
presentation. However, aspirin and NSAIDS are two of the most 
common causes of drug-induced anaphylaxis. Aspirin influences 
the pathogenesis of anaphylaxis through cyclooxygenase 
inhibition, by shunting arachidonic acid into the leukotriene 
pathway, producing more anaphylaxis mediators.117
In the type III variant, in addition to ACS treatment, aspiration of 
the intra-stent thrombus should be considered, followed by 
histological examination of the clot (staining for mast cells and 
eosinophils).102
Based on pathophysiological findings, mast cell blockers have 
been proposed as potential therapeutic agents.70,71 Disodium 
cromoglycate seems ineffective; however, the flavonoid 
quercetin showed some promise.118 Mast cell stabilisation may 
be an important future therapeutic option for Kounis syndrome.
Controversies regarding adrenaline
The use of adrenaline in anaphylaxis is based on a century of 
clinical experience, epidemiological studies,119 fatality 
studies81,120,121 and prospective studies,4,30,122 as well as in-vitro123 
and animal studies.103,104,124
Delayed administration of adrenaline in anaphylaxis is associated 
with increased mortality.81,120,121,124 Furthermore, animal models 
suggest that giving adrenaline in established anaphylactic shock 
does not hasten recovery, and may cause LV impairment.124,125 In 
practice it is a difficult balance between timeous administration 
to those needing it and avoiding it for low-grade anaphylactic 
reactions.
Apical ballooning syndrome (ABS), or Tako-Tsubo cardiomyopathy 
(a reversible left ventricular dysfunction) is thought to be a result 
of excess catecholamine stimulation of the heart, with several 
pathophysiological postulates (epicardial coronary artery spasm, 
It should be performed based on clinical history, with the aim to 
prove the pathophysiological mechanism and identify a culprit 
to avoid next time.
Treatment
At present there are no clear treatment guidelines for Kounis 
syndrome; most of the data are derived from case reports. Two 
aspects need treatment, (1) the allergic reaction and (2) the acute 
coronary syndrome (ACS). Treating the hypersensitivity reaction 
may abolish the type I variant, but the type II variant often needs 
ACS treatment in addition.
Allergic reaction/anaphylaxis
The World Allergy Organization recently published a consensus 
document summarising the evidence-based anaphylaxis 
guidelines developed and published independently from 2010 
to 2014 by four allergy/immunology organisations.92 More 
specifically, there are numerous protocols for perioperative 
anaphylaxis.93,94 It is recommended to follow one of these.
The first-line pharmacologic treatment is prompt injection of 
adrenaline,92,95 although this is not supported by any randomised 
controlled trial.95,96 In addition to the cardiovascular and 
respiratory beneficial effects, it suppresses further mediator 
release from mast cells and basophils during anaphylaxis (via β2-
adrenergic receptors).97 The therapeutic plasma concentration of 
adrenaline for successful treatment of anaphylaxis is unknown. 
However, one should titrate small intravenous boluses to clinical 
effect, the dose depending on clinical presentation (using the 
Ring and Messmer grading scale).88,98,99 Some authors suggest 
never using adrenaline in grade I reactions.47
IV fluids (crystalloids) should be given to compensate for the 
intravascular loss, as up to 35% of the intravascular volume can 
leak into the extravascular space within 10 minutes.100
Although most guidelines advocate the use of anti-histamines 
and glucocorticoids, no robust studies confirming the 
effectiveness of these treatments exist.95,101 However, in those 
with type I variant and milder grades of anaphylaxis, 
hydrocortisone (1–2 mg/kg/day) and H1 plus H2-antihistamines 
(diphenhydramine 1–2 mg/kg and ranitidine 1 mg/kg) may be 
adequate treatment.102
Refractory anaphylaxis should be managed with a continuous 
infusion of vasopressors rather than IV boluses, but only by those 
experienced with their use.103 In addition, vasopressin,104–106 
glucagon,107,108 anti-cholinergic drugs (atropine), methylene 
blue,109 and α1-agonists
110–112 are all proposed treatments for 
refractory cases.
Acute coronary syndromes
The treatment of acute coronary syndromes is based on the 
latest ACC/AHA guidelines, and will depend on the 
presentation.113,114 In those with an ST-elevation myocardial 
infarction (STEMI) the focus is on obtaining an urgent angiogram, 
with subsequent management dependent on findings (medical 
therapy, percutaneous coronary intervention or coronary artery 
bypass grafting). Note that fibrinolytics like streptokinase carry a 
high risk of anaphylaxis.115
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microvascular spasm, or direct myocyte injury).126 There are 
several reports in the literature of ABS following adrenaline 
therapy during anaphylaxis.127–134
While it is the first-line therapy in anaphylaxis, its use in acute 
coronary syndromes is a slightly more challenging decision. It 
can cause serious side effects like arrhythmias (e.g. tachycardia 
leading to aggravated myocardial ischaemia), hypertension 
(causing intra-cerebral bleeds, pulmonary oedema etc.) and 
coronary vasospasm. Elderly patients and those with a history of 
hypertension, peripheral vascular disease, ischaemic heart 
disease and untreated hyperthyroidism are especially prone to 
these side effects.135 A study looking at fatal anaphylaxis 
attributed 3 out of 20 (15%) deaths directly to adrenaline 
overdose.120
Adrenaline is not an innocuous drug in anaphylaxis. It has a narrow 
therapeutic index97, and should be carefully titrated to effect.
Prognosis
This will depend on the magnitude of the initial reaction, which 
in turn depends on the patient’s sensitivity (i.e. previous 
exposure), other comorbidities (e.g. pre-existing coronary 
atherosclerosis80,81,136 and mastocytosis39,137,138), the site of 
antigen–antibody reaction, the allergen concentration and the 
route of allergen entrance (e.g. intravenous versus topical).
The prognosis is generally good beyond the acute phase, with 
left ventricular function recovering over three days to several 
weeks. In the acute phase patients may develop life-threatening 
arrhythmias, pulmonary oedema and plaque rupture leading to 
a coronary thrombus, but fortunately death is rare.139
There are some reports that the type I variant of Kounis has a 
better prognosis than type II.33
Conclusions
Mediators released from cardiac mast cells during a hypersensitivity 
reaction are key to the subsequent adverse CVS effects. It would be 
prudent to actively look for cardiac involvement whenever 
hypersensitivity is suspected, keeping in mind that patients with 
cardiovascular disease have a significantly higher risk of developing 
severe or fatal anaphylaxis.80,81 Additionally, commonly used CVD 
drugs such as β blockers and ACE inhibitors could exacerbate 
anaphylaxis and make it resistant to treatment.140
Adrenaline remains the first-line treatment for higher-grade 
anaphylaxis. However, in those with CVD (and specifically ACS) it 
needs to be carefully considered, weighing the side effects of 
adrenaline against the risks of untreated anaphylaxis. There is 
scope to develop multispecialty guidelines to manage this 
complex condition.
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